Events & Presentations

Archived Investor Events and Presentations

Archived Scientific Presentations

Date	Event Details
Summary Toggle Jun 15, 2020	Raymond James Human Health Innovation Conference
Summary Toggle Jun 02, 2020 at 2:30 PM EDT	Jefferies Virtual Healthcare Conference Listen to webcast
Summary Toggle May 20, 2020 at 4:15 PM EDT	2020 RBC Capital Markets Global Healthcare Virtual Conference Listen to webcast
Summary Toggle May 07, 2020 at 4:30 PM EDT	Q1 2020 Xencor, Inc. Earnings Conference Call Listen to Webcast

Date	Documents
Jun 22, 2020	Add Files AACR 2020: XmAb30819, an XmAb® 2+1 ENPP3 x CD3 bispecific antibody for RCC, demonstrates safety and efficacy in in vivo preclinical studies 792.7 KB
Jun 22, 2020	Add Files AACR 2020: Affinity tuned XmAb®2+1 PSMA x CD3 bispecific antibodies demonstrate selective activity in prostate cancer models 794.3 KB
Jun 22, 2020	Add Files AACR 2020: Affinity tuned XmAb® 2+1 anti-mesothelin x anti-CD3 bispecific antibody induces selective T cell-dependent cellular cytotoxicity of human ovarian cancer cells 810.3 KB
Jun 22, 2020	Add Files AACR 2020: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity 1.1 MB
Dec 09, 2019	Add Files ASH 2019: Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with R/R NHL and CLL 520.4 KB
Mar 04, 2019	Add Files Festival of Biologics USA 2019: Tumor selective cytotoxicity by TAA x CD3 bispecifics utilizing a 2:1 mixed-valency format 891.8 KB
Dec 03, 2018	Add Files ASH 2018: Complete Responses in r/r AML Patients on a Weekly Dosing Schedule of XmAb®14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study 943.5 KB
Dec 03, 2018	Add Files ASH 2018: Regulatory T cell selective IL-2-Fc fusion proteins for the treatment of autoimmune diseases 8 MB
Nov 09, 2018	Add Files SITC 2018: Simultaneous checkpoint-costimulatory or checkpoint-checkpoint receptor targeting with bispecific antibodies promotes enhanced human T cell activation 699.4 KB
Nov 09, 2018	Add Files SITC 2018: An IL15/IL15Rα heterodimeric Fc-fusion engineered for reduced potency demonstrates an optimal balance of in vivo activity and exposure 1.3 MB
Oct 21, 2018	Add Files ACR 2018: Top-line Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study of a Reversible B Cell Inhibitor, XmAb®5871, in Systemic Lupus Erythematosus (SLE) 4 MB
Apr 18, 2018	Add Files AACR 2018: Potency-reduced IL15/IL15Rα heterodimeric Fc-fusions display enhanced in vivo activity through increased exposure 739.8 KB
Apr 16, 2018	Add Files AACR 2018: Simultaneous checkpoint-checkpoint or checkpoint-costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation 703.1 KB
Nov 13, 2017	Add Files SITC 2017: Anti-PD1 x anti-ICOS bispecific antibody XmAb23104 brings together PD1 blockade and ICOS costimulation to promote human T cell activation and proliferation 1.4 MB
Nov 13, 2017	Add Files SITC 2017: Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T Cell Activation and Proliferation 893.1 KB
Nov 08, 2017	Add Files ACR 2017: Final Results from Phase 2 Study of XmAb 5871 in IgG4-Related Disease 1 MB
Jun 16, 2017	Add Files EULAR 2017: Interim Results of a Phase 2 Study of XmAb®5871, a Reversible B Cell Inhibitor, in IgG4-Related Disease 945 KB
Apr 04, 2017	Add Files AACR 2017: Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors 2.1 MB
Apr 04, 2017	Add Files AACR 2017: IL 15/IL 15Ra; heterodimeric Fc-fusions with extended half-lives 2.3 MB
Apr 04, 2017	Add Files AACR 2017: Combination of PD1 blockade and T cell costimulation by bispecific antibodies promotes human T cell activation and proliferation 2.7 MB
Nov 13, 2016	Add Files Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease 1.4 MB
Nov 13, 2016	Add Files Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease 1.4 MB
Nov 09, 2016	Add Files 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Dual Blockade of PD-1 and CTLA-4 with Bispecific Antibodies Promotes Human T cell Activation and Proliferation 1 MB
Nov 09, 2016	Add Files 2016 Society for Immunotherapy of Cancer (SITC) Annual Meeting Poster: Multiple Bispecific Checkpoint Combinations Promote T cell activation 1.1 MB
May 18, 2016	Add Files American Thoracic Society: ATS Conference 2016: A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195 1 MB
Jun 12, 2015	Add Files European League Against Rheumatism (EULAR) 2015 Annual Meeting Poster: A Phase 1b/2a Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XmAb®5871 in Patients with Rheumatoid Arthritis 1.1 MB
Dec 08, 2014	Add Files American Society of Hematology 2014 Annual Meeting Poster: Anti-CD38 × Anti-CD3 Bispecific Antibodies in Multiple Myeloma Chu, et al, Abstract ID# 4727 3.7 MB
Dec 07, 2014	Add Files Xencor American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD123 x Anti-CD3 Bispecific Antibodies in Acute Myleogenous Leukemia Chu, et al, Abstract ID# 2316 4.1 MB
Dec 07, 2014	Add Files American Society of Hematology 2014 Annual Meeting Poster: XmAb Anti-CD20 × Anti-CD3 Bispecific Antibodies in B-cell Lymphomas and Leukemia Chu, et al, Abstract ID# 3111 3.5 MB

Tools

Events & Presentations

Upcoming Events

Archived Investor Events and Presentations

Archived Scientific Presentations

Raymond James Human Health Innovation Conference

Jefferies Virtual Healthcare Conference

2020 RBC Capital Markets Global Healthcare Virtual Conference

Q1 2020 Xencor, Inc. Earnings Conference Call